- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06209541
Internet-based Cognitive Behavioral Therapy: a Factorial Randomized Controlled Trial About Treatment Content and Support
Tailored or Transdiagnostic ICBT with a Specific Therapist or Team Support: a Factorial Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a factorial randomized controlled trial with the aim to investigate ICBT with two kinds of treatment contents and two kinds of support. Participants will either be randomized to an individually tailored treatment, where they will be selecting their own modules that they wish to work with, or be randomized to a transdiagnostic treatment, that consists of Unified Protocol that is developed by David Barlow and colleagues. Participants will also be randomized to either get weekly support by one specific therapist or get support by "a team", meaning that the participant will get support from different therapists each week. In both kinds of support, the participant will have the opportunity to ask for support during the other times of the week as well.
Primary outcome measures are depression symptoms (measured with Beck Depression Inventory-II) and anxiety symptoms (measured with Beck Anxiety Inventory). Other, secondary, outcome measures used will for example be about stress symptoms, insomnia symptoms, and quality of life. Pre-treatment measurement, post-treatment measurement and one-year follow up is planned to be collected through an online survey.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Linköping, Sweden
- Linköping University
-
-
Östergörland
-
Linköping, Östergörland, Sweden, 58183
- Department of Behavioral Sciences and Learning
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Experience mild to moderate psychological symptoms or problems
- 18 years or older
- Ability to speak, read and write in Swedish
- Have access to the internet and a smartphone, computer or other device
Exclusion Criteria:
- Severe psychiatric or somatic illness that makes participation harder or impossible
- Ongoing addiction
- Acute suicidality
- Other ongoing psychological treatment
- Recent (within the latest month) changes in the dose of psychotropic medication or planned change of dose during the treatment weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Unified Protocol, support by a specific therapist
The participants receive eight weeks of ICBT, based on the treatment manual Unified Protocol by David Barlow and colleagues (2013), with weekly support by a specific therapist that follow the individual participant through all treatment weeks.
During the eight weeks, the participant will receive in total eight treatment modules.
|
All participants get treatment and are thus included in experimental groups, no matter the randomization result.
It consists of eight treatment weeks with weekly support.
The treatment format will differ between the four groups, depending on type of treatment content and type of support.
|
|
Experimental: Unified Protocol, support by a team
The participants receive eight weeks of ICBT, based on the treatment manual Unified Protocol by David Barlow and colleagues (2013), with weekly support by a team of therapists.
This arm implies that the participant will get support from different therapists each week.
During the eight weeks, the participant will receive in total eight treatment modules.
|
All participants get treatment and are thus included in experimental groups, no matter the randomization result.
It consists of eight treatment weeks with weekly support.
The treatment format will differ between the four groups, depending on type of treatment content and type of support.
|
|
Experimental: Individually tailored treatment, support by a specific therapist
The participants receive ICBT in an individually tailored format, where they get to select which modules they want to be included in their specific treatment.
The participants are recommended to select eight modules (out of 25) and work with one modules each week, but this is only recommendations.
In their treatment, weekly support by a specific therapist that follow the individual participant through all treatment weeks is included.
|
All participants get treatment and are thus included in experimental groups, no matter the randomization result.
It consists of eight treatment weeks with weekly support.
The treatment format will differ between the four groups, depending on type of treatment content and type of support.
|
|
Experimental: Individually tailored treatment, support by team
The participants receive ICBT in an individually tailored format, where they get to select which modules they want to be included in their specific treatment.
The participants are recommended to select eight modules (out of 25) and work with one modules each week, but this is only recommendations.
In their treatment, weekly support by a team of therapists is included.
This arm implies that the participant will get support from different therapists each week.
|
All participants get treatment and are thus included in experimental groups, no matter the randomization result.
It consists of eight treatment weeks with weekly support.
The treatment format will differ between the four groups, depending on type of treatment content and type of support.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Becks Depression Inventory-II
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of depressive symptoms.
Range for the total sum is between 0 and 63 with a higher score indicating a higher level of depressive symptoms.
Clinical ranges for minimal, mild, moderate and severe major depressive disorder are considered to be 0-13, 13-19, 20-28, and 29-63 points respectively.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Beck Anxiety Inventory
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of anxiety symptoms, consisting of 21 items.
Range for the total sum is between 0 and 63, interpreted as minimal anxiety (0-7), mild anxiety (8-15), moderate anxiety (16-25) and severe anxiety (26-63).
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Alcohol Use Disorder Identification Test
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A 10-item screening tool to assess alcohol consumption, drinking behaviors, and alcohol-related problems.
10 items and scores ranging from 0-40 with higher scores indicating a higher level of alcohol use.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Brunnsviken Brief Quality of Life Scale
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of quality of life with a total score ranging from 0 to 96 with a higher score indicating a higher quality of life.
The scores of each of the six primary questions regarding perceived quality of life within an area of life are multiplied with the score of an item measuring the perceived importance of the area in question.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Perceived Stress Scale-14
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A questionnaire that aims to measure symptoms of stress.
I contains 14 items that are scored on a range between 0 (never) to 4 (very often).
The total score range is between 0-56 and a higher score reflects higher levels of perceived stress.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Insomnia Severity Index
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of insomnia severity and symptoms of disordered sleep.
Norm score ranges include low likelihood of sleep problems (0 to 7 points), some sleep problems (8 to 14 points), moderate sleep problems (15 to 21 points), severe sleep problems (22 to 28 points).
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Patient Health Questionnaire-15
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of somatic symptoms.
It consists of 15 items for women and 14 items for men (because the item about "menstrual cramps or other problems with your periods" are removed).
The symptoms are rated on a scale from 0 (not bothered) to 2 (bothered a lot).
Total score ranges from 0 to 30 for women and 0 to 28 for men.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Goldberg's (1999) IPIP representation of Costa McCrae's (1992) NEO-PI-R Domains
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of neuroticism.
It consists of 10 items, scored from 0 (Very inaccurate) to 4 (Very accurate).
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
InCharge Financial Distress/Financial Well-Being Scale
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A measure aiming to measure distress related to the individual's economic situation.
It contains of eight questions where the respondent gets to answer on a scale from 1 to 10.
A higher score indicates lower economic distress.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Rosenberg's Self-esteem Scale
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of self-esteem, consisting of ten items where five of them are positively and five of them are negatively worded.
Sum scores range between 0-30.
A higher score indicates higher self-esteem.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knowledge test (created by the research team)
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Knowledge test about cognitive behavior therapy and how strategies in cognitive behavior therapy can be applied in every day situations.
It consists of 16 questions and the respondent gets three answer options while one of the alternatives are correct.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gerhard Andersson, PhD, University Hospital, Linkoeping
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- INES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety Symptoms
-
Boston Medical CenterPatient-Centered Outcomes Research Institute; Boston University; Johns Hopkins... and other collaboratorsCompletedAnxiety Disorders | Anxiety | Anxiety Symptoms | Child Anxiety | Anxiety, Mild to Moderate | Pediatric Anxiety DisordersUnited States
-
UCLH/UCL Joint Research OfficeMedical Research Council; Camden and Islington NHS Trust; Central and North West...RecruitingAnxiety Disorders | Anxiety | Anxiety Depression | CBT | Anxiety Disorders and Symptoms | Anxiety Generalized | Generalised Anxiety Disorder | Anxiety Disorder; Mixed With Depression (Mild) | Anxiety Disorder GeneralizedUnited Kingdom
-
University of AlcalaCompletedAnxiety | Depressive Symptoms | Anxiety Symptoms | Subthreshold DepressionSpain
-
Aveiro UniversityFoundation for Science and TechnologyNot yet recruitingAnxiety Disorders | Anxiety SymptomsPortugal
-
International Association Psychosomatics And Health...RecruitingAnxiety | Anxiety DepressionUkraine
-
Tribhuvan University Teaching Hospital, Institute...CompletedAnxiety Disorder/Anxiety StateNepal
-
Linkoeping UniversityActive, not recruitingDepressive Symptoms | Anxiety SymptomsBrazil
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
University of WindsorAnxiety CanadaCompletedDepression | Anxiety | Anxiety Disorders and Symptoms | Anxiety GeneralizedCanada
-
Babes-Bolyai UniversityRecruitingDepression | Anxiety | Death AnxietyRomania
Clinical Trials on Internet-based cognitive behavioral therapy (ICBT)
-
Karolinska InstitutetDeakin UniversityRecruiting
-
Umeå UniversityCompleted
-
Linkoeping UniversityRecruiting
-
Jouf UniversityCompletedPregnant Women | Self Efficacy | Fear of Childbirth | Cognitive Behavioral TherapyEgypt
-
Region of Southern DenmarkUniversity of AarhusRecruitingAnxiety DisordersDenmark
-
University of AarhusUniversity of Southern DenmarkCompletedAnxiety DisordersDenmark
-
Karolinska InstitutetCompletedObsessive-compulsive DisorderSweden
-
Okan UniversityCompletedDepression | Breast Cancer | Anxiety | Traumatic Stress | Quality of LifteTurkey
-
Vilnius UniversityCompletedSleep | Tinnitus | Depression, Anxiety | Distress, EmotionalLithuania
-
Örebro County CouncilKarolinska InstitutetCompleted